The Motley Fool··Jonathan PoncianoBiotech Fund Trims $14M Dyne Position Despite 40% Stock Surge
Saturn V Capital sold $14.17M in Dyne shares despite 40% appreciation, retaining nearly 1M shares ahead of expected Q2 BLA submission.
DYNFDA approvalclinical-stage biotech